HematologyNews.net

Hematology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Exjade reduces iron overload in patients with non-transfusion-dependent thalassemia


Results from THALASSA, the first pivotal placebo-controlled study examining the benefit of iron chelation with Exjade ( Deferasirox ) in patients with non-transfusion-dependent thalassemia ( NTDT ), were presented at 53rd Annual Meeting of the American Society of Hematology and have shown that Exjade can significantly reduce iron overload.

THALASSA investigated whether patients with NTDT and iron overload can benefit from iron chelation therapy as determined by liver iron concentration ( LIC ).

The study met its primary endpoint, showing that Deferasirox at a 10mg/kg/day starting dose significantly reduced LIC from baseline by 3.8 mg of iron per gram of liver dry weight ( Fe/g dw ) compared to an increase of 0.38 mg Fe/g dw in patients on placebo ( p less than 0.001 ). The study also determined that a 10 mg/kg/day dose was superior to a 5 mg/kg/day dose ( p=0.009 ).

In the 10 mg/kg arm, 49% of patients had a LIC decrease of at least 30% from baseline versus only 2% in the placebo arm. In addition, 56% of patients in the 10 mg/kg arm had a LIC decrease of greater than or equal to 3 mg at one year compared to 11% in the placebo arm.

The most common adverse events reported were nausea, rash, diarrhea, headache and upper abdominal pain.
Adverse events were similar in all patient groups, including the placebo arm.

Thalassemia refers to a diverse group of genetic disorders that affect red blood cell production, causing anemia. Unlike types of thalassemia in which patients require regular blood transfusions, NTDT patients can live without frequent transfusions. However, patients with NTDT are still at risk of accumulating excess iron.

NTDT refers to a group of clinically milder forms of thalassemias, including beta-thalassemia intermedia, Hemoglobin H disease ( Hb H-alpha-thalassemia ) and Hemoglobin E / beta-thalassemia.
Despite a slower rate of iron accumulation, the burden of iron overload in NTDT patients is similar to that observed in thalassemia patients who receive regular blood transfusions.
NTDT patients are not symptomatic at birth, when most thalassemias are diagnosed. Therefore they are often underdiagnosed and untreated even when symptoms appear at age 10 or later. NTDT is most commonly found in Southeast Asian, South Asian, Middle Eastern and Mediterranean populations.

The THALASSA study assessed the efficacy of Exjade versus placebo in NTDT patients greater than or equal to 10 years of age with iron overload.

THALASSA was a one-year, randomized, double-blind, placebo-controlled pivotal study, including 166 patients with beta-thalassemia intermedia ( n=95 ), alpha-thalassemia ( n=22 ) or Hemoglobin E / beta-thalassemia ( n=49 ).
Patients greater than or equal to 10 years of age with LIC greater than or equal to 5 mg Fe/g dw and serum ferritin greater than 300 ng/mL were randomized to starting Exjade doses of 5 mg/kg/day ( n=55 ) or matching placebo ( n=28 ) and 10 mg/kg/day ( n=55 ) or matching placebo ( n=28 ).

Exjade is indicated for the treatment of chronic iron overload due to blood transfusions ( transfusional hemosiderosis ) in adult and pediatric patients ( aged 2 years and over ).

Exjade is contraindicated in patients with an estimated creatinine clearance less than 60 mL/min, with hypersensitivity to the active substance or any of the excipients, or in combination with other iron chelator therapies. Exjade is not recommended in patients with severe hepatic impairment.

There have been postmarketing reports of acute renal failure, hepatic failure, and cytopenias. Renal failure requiring temporary or permanent dialysis, renal tubulopathy, and interstitial nephritis have been reported. Upper gastrointestinal ulceration and hemorrhage, sometimes fatal, have been reported. Caution should be used in elderly patients due to a higher frequency of adverse reactions. Exjade is not recommended in patients with a short life expectancy ( e.g., high-risk myelodysplastic syndromes ), especially when co-morbidities could increase the risk of adverse events.

Skin rashes, serious hypersensitivity reactions, decreased hearing, and lens opacities have been reported.
The most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain, rash, non-progressive increases in serum creatinine, increased transaminases, abdominal distension, constipation, dyspepsia, proteinuria, and headache. ( Xagena )

Source: Novartis, 2011

XagenaMedicine_2011



Indietro